HMO sourcing should not be treated as conventional ingredient procurement. Human milk oligosaccharides are structurally complex glycans, produced using precision fermentation, and small differences can carry product implications. Purity is part of quality management, food safety, and regulatory confidence. The end applications, particularly infant formula, leave little room for error, as the consumer population is uniquely vulnerable.
Regulatory burden also changes the procurement equation. HMO approvals are often tied to a defined identity, production process, specification, and intended use. In some markets, status can depend on the supplier dossier or notified material, not only the generic HMO name. A sourcing decision may influence filings, label claims, launch timing, and post-market risk. Certain fermentation strains, processes, compositions, and applications may also be covered by active patents.
For more on HMO structure, function, and application, see our full guide on Human Milk Oligosaccharides (HMOs): from production to applications.
The following criteria reflect procurement priorities and scientific requirements behind HMO ingredient selection. Each connects commercial due diligence with formulation, quality, regulatory, and technical risk. Every criteria follows the same structure: what it is, why it matters, and what to ask.
What to assess: Supplier evaluation should begin with confirmed HMO identity, followed by a detailed review of purity, food safety parameters, and batch-level release testing. Many commercial HMOs aim for a minimal purity in the range of 80 to 94%, depending on the type of HMO. However, purity percentage alone is not sufficient to assess overall material quality. Batch-level testing is also essential because it confirms whether the supplied material consistently meets agreed release specifications. A strong CoA should align with agreed purity specifications and cover testing of purity, residual protein, microbial burden, endotoxin, heavy metals, moisture, and relevant process-related parameters, and at the same time keep the target application in mind (e.g. targeting the infant vs adult population). The exact analytical methods used to generate this data are equally important.
Why it matters: The quality and completeness of the CoA provide important evidence of the supplier’s process control, analytical maturity, and quality culture. Missing parameters, vague analytical methods, or inconsistent specifications should be treated as clear supplier qualification risks. These gaps may indicate that the manufacturing process, analytical control strategy, or documentation system is not yet sufficiently mature for commercial use.
What to ask: Request the specification sheet and, as soon as material is available, a batch-specific CoA. It should cover data on purity, microbial burden, endotoxin, heavy metals, moisture, and agreed release parameters. Also, confirm which quality and food safety certifications are currently held. Ask for sample material to evaluate the powder characteristics yourselves.
What to assess: Regulatory approval status should be reviewed separately for each HMO structure, intended use, and target market. A supplier may have FDA GRAS, EU Novel Food, or market-specific access through another route, but the scope and conditions of that access require careful verification.
Why it matters: Approval does not follow the ingredient name alone. In some markets, it can be structure-specific and supplier-specific. Authorities often look at the exact production process, specification, exposure level, and safety dossier behind the material. A change of supplier can affect registration, formulation timelines, label review, and launch planning.
What to ask: Ask for the GRAS notice number, the Novel Food Union list reference and whether its production strain and specification fall within that entry, or any other relevant regulatory documentation. Then check the details. Which markets are covered? Which HMO structures, specifications, production processes, and intended applications does that coverage actually apply to?
What to assess: The commercial scale should be assessed before a formulation becomes dependent on a specific HMO material. Ask early about production capacity, batch sizes, lead times, HMO minimum order quantity (MOQ), and packaging and delivery format. Portfolio breadth is another practical check. A single-HMO supplier may work for a focused product, but multi-ingredient programmes often demand a broader supply foundation. That means looking beyond what each supplier is able to deliver today (e.g. a single HMO), as its innovation ingredient pipeline could provide future opportunities for next-generation products.
Why it matters: Research quantities can make a supplier look ready before the commercial details have been tested. A material may be available for lab trials, but that does not always mean the supplier can meet larger batch requirements, fixed lead times, or repeat supply over a launch period. MOQ, delivery format, and batch availability should therefore be checked early on.
What to ask: What annual capacity is available for this HMO? What are the standard batch sizes, MOQ, lead times, and delivery formats? How flexible is the supplier to accommodate deviations from the standard supply terms? Can the supplier support single HMOs, blends, and future pipeline ingredients if the product range expands?
What to assess: Capacity alone does not prove supply chain reliability. Where and how the HMO is produced, in own or contracted and qualified facilities, matters just as much. Fermentation-based HMO processes often rely on lactose and other feedstocks, so availability, quality, and supplier controls need a practical check. For fermentation-based production, raw material sourcing, production concentration, and overall capacity should be reviewed before commercial commitments are made.
Why it matters: HMO projects often involve long development, regulatory, and validation timelines. Once a formulation is locked, switching suppliers is rarely quick. It may trigger new testing, document review, and possible regulatory assessment.
What to ask: Where is the HMO manufactured? If production gets interrupted, what backup is already in place? Ask whether the supplier has multi-site capabilities, qualified backup sites, or backup agreements. What is the supplier’s change control procedure and notification policy?
What to assess: A good HMO supplier does more than deliver the ingredient. It should also know its HMOs thoroughly and share that knowledge. This includes a full ingredient specification, validated analytical methods and data on how the HMO behaves under conditions that matter for processing. Some suppliers also have application experience in certain product formats and can share practical guidance. During evaluation, ask for the ingredient data that feeds your formulation work, such as stability, solubility and processing behaviour. Then check how far the supplier’s support goes beyond that.
Why it matters: HMOs are structurally complex, biologically relevant and sensitive from a regulatory point of view. Reliable ingredient data and responsive technical contacts help you avoid delays and repeated testing. This matters most in infant nutrition, medical nutrition, supplements, functional foods and research applications, where every formulation question that goes unanswered costs development time. Knowing early where the supplier’s expertise ends lets you plan which formulation work you will do in house or with external partners.
What to ask: Which stability and solubility data are available for the HMO, and under which conditions were they generated? Does the supplier provide validated analytical methods, or help you choose one? Does it have application experience in your product format, and can it share examples? Where its support ends, can it refer you to formulation or manufacturing partners?
|
Criteria |
What to request |
Red flag |
|
|
1.Analytical quality / CoA |
Specification sheets, batch-specific CoA, food safety certifications and sample material |
Missing parameters or no quality certifications |
|
|
2.Regulatory status |
GRAS notice or Novel Food dossier reference per HMO structure |
Vague claims or no dossier number |
|
|
3.Scale, MOQ & portfolio |
Production capacity, lead times, MOQ, formats, portfolio breadth and innovation pipeline |
No commercial-scale track record or single ingredient supplier only |
|
|
4.Supply reliability |
Manufacturing site details, raw material sourcing, and backup supply plan |
No qualified production sites available |
|
|
5.Technical support |
Stability and solubility data, analytical methods, application experience |
No or limited support available |
|
Talk to our HMO experts to discuss your supplier evaluation criteria.
Supplier review should start with a specification sheet, followed by a batch-specific certificate of analysis (CoA) as soon as material is available. It should cover identity, purity specifications, endotoxin, heavy metals, moisture, residual protein, and the relevant microbiological or food safety parameters. Quality management and food safety certifications should also be reviewed before supplier approval.
Not always. A supplier’s regulatory status can depend on the exact structure, how it is produced, the agreed specification, the safety dossier, the target market, and the intended use. An approved HMO name is not enough on its own. Procurement and regulatory teams should check the specific GRAS, Novel Food, or target-market reference before relying on that supplier for a project.
HMO minimum order quantity varies by structure, delivery format, production scale, and supplier model. Research quantities may be available in grams or kilograms. Commercial supply usually involves larger batch commitments. MOQ should be reviewed together with lead time, annual capacity, and the launch forecast.
Expect solid support on the ingredient itself: a full specification, a batch-specific CoA, stability and solubility data, and help choosing an analytical method to quantify the HMO in your product. Some suppliers can also share application experience in specific formats, such as powders, liquids or tablets, and give practical guidance on processing.
Structural identity is usually confirmed through validated analytical methods, reference standards, chromatographic profiling, and development-stage structural confirmation. NMR can support development and validation work, but it is not typically performed on every released batch. Routine release testing should still confirm identity against agreed specifications.
Reliable supply is not just about having material available right now. It also means qualified manufacturing sites, controlled raw material sourcing, inventory planning, and backup options where needed. Single-site production can create continuity risk. A reliable supplier should be able to explain the basics clearly: where production takes place, how feedstock sourcing is controlled, what redundancy plans exist, and how lead times or disruption procedures are managed.
Research-grade HMOs have a place in screening, proof-of-concept work and in vitro and in vivo research studies. They are typically supplied in small quantities for laboratory or study use, without the full quality documentation, regulatory coverage and supply commitments that commercial-grade material needs for products placed on the market. For a commercial formulation, the question is different: can the supplier support the material with clear specifications, reliable batch records, food safety controls, regulatory documentation, scalable supply, and defined release testing?
While Inbiose strives to ensure the accuracy and timeliness of the information presented in this document, the company makes no guarantees or assurances regarding the precision, reliability, or completeness of the content. This information is intended solely for scientific and technical purposes in business-to-business communications. Local regulations and requirements should be reviewed when considering product labeling or advertising to end consumers. The information provided does not constitute medical or scientific advice, diagnosis, or treatment, and is offered without any warranties, express or implied. Inbiose shall not be held liable for any damages resulting from the use or interpretation of the material presented herein. The reader assumes full responsibility for their use of the information. No liability is accepted for any infringement of patents resulting from the use of the information provided. Content may be updated without prior notice. For further information, please contact your local Inbiose representative. All trademarks mentioned are owned by or licensed to Inbiose unless otherwise noted.
